In this article, Deborah A. Komlos at Clarivate Analytics describes
the high importance of the communications between sponsors and
the US Food and Drug Administration (FDA) in the process of drug
development, having a shared public health goal of early availability
of safe, effective, and high-quality drugs. According to the FDA,
the timely review of IND submissions with appropriate feedback
to sponsors can improve the efficiency of the drug development
process.